4.5 Review

The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00406-017-0820-z

关键词

Gut microbiome; Gut brain axis; Schizophrenia; Antipsychotic-induced weight gain

资金

  1. Canadian Institutes of Health Research (CIHR) [MOP 142192]
  2. Centre for Addiction and Mental Health (CAMH) Foundation
  3. Generation Capital Award
  4. Farncombe Family Digestive Health Research Institute
  5. CAMH Foundation

向作者/读者索取更多资源

With the emergence of knowledge implicating the human gut microbiome in the development and regulation of several physiological systems, evidence has accumulated to suggest a role for the gut microbiome in psychiatric conditions and drug response. A complex relationship between the enteric nervous system, the gut microbiota and the central nervous system has been described which allows for the microbiota to influence and respond to a variety of behaviors and psychiatric conditions. Additionally, the use of pharmaceuticals may interact with and alter the microbiota to potentially contribute to adverse effects of the drug. The gut microbiota has been described in several psychiatric disorders including depression and anxiety, but only a few reports have discussed the role of the microbiome in schizophrenia. The following review examines the evidence surrounding the gut microbiota in behavior and psychiatric illness, the role of the microbiota in schizophrenia and the potential for antipsychotics to alter the gut microbiota and promote adverse metabolic events.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Neurosciences

Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study

Prabhjot Dhami, Lena C. Quilty, Benjamin Schwartzmann, Rudolf Uher, Timothy A. Allen, Stefan Kloiber, Raymond W. Lam, Glenda MacQueen, Benicio N. Frey, Roumen Milev, Daniel J. Mueller, Stephen C. Strother, Pierre Blier, Claudio N. Soares, Sagar V. Parikh, Gustavo Turecki, Jane A. Foster, Susan Rotzinger, Sidney H. Kennedy, Faranak Farzan

Summary: The neurobiological correlates of response inhibition can predict the response of patients with major depressive disorder (MDD) to pharmacological and cognitive behavioral therapy treatment. The integrity of response inhibition may be crucial for the success of treatment for MDD. Electrophysiological correlates of response inhibition may serve as a general prognostic marker for treatment response in MDD.

BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING (2023)

Article Pharmacology & Pharmacy

Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study

Helena K. Kim, Gwyneth Zai, Daniel J. Mueller, Muhammad Husain, Raymond W. Lam, Benicio N. Frey, Claudio N. Soares, Sagar Parikh, Roumen Milev, Jane A. Foster, Gustavo Turecki, Faranak Farzan, Benoit H. Mulsant, Sidney H. Kennedy, Shreejoy J. Tripathy, Stefan Kloiber

Summary: This study explores the relationship between the endocannabinoidome and major depressive disorder (MDD), and identifies lower methylation levels of the DAGLA gene as a potential marker for treatment outcomes in MDD. Further research is needed to explore the significance of DAGLA methylation in MDD treatment.

PHARMACOPSYCHIATRY (2022)

Article Psychology, Clinical

Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 report

Mehri Sajjadian, Rudolf Uher, Keith Ho, Stefanie Hassel, Roumen Milev, Benicio N. Frey, Faranak Farzan, Pierre Blier, Jane A. Foster, Sagar Parikh, Daniel J. Mueller, Susan Rotzinger, Claudio N. Soares, Gustavo Turecki, Valerie H. Taylor, Raymond W. Lam, Stephen C. Strother, Sidney H. Kennedy

Summary: Predicting treatment outcomes for major depressive disorder can be improved by combining clinical, neuroimaging, and molecular data. Early measurement during treatment can increase precision, but adding more features does not necessarily enhance prediction accuracy.

PSYCHOLOGICAL MEDICINE (2023)

Article Clinical Neurology

Neurovascular correlates of retinal microvascular caliber in adolescent bipolar disorder

Megan Mio, Anahit Grigorian, Yi Zou, Mikaela K. Dimick, Beth Selkirk, Peter Kertes, Brian W. McCrindle, Walter Swardfager, Margaret K. Hahn, Sandra E. Black, Bradley J. MacIntosh, Benjamin I. Goldstein

Summary: This study reveals an association between retinal vascular caliber and cerebral blood flow in adolescents with bipolar disorder. These findings provide important insights into the potential neurofunctional mechanisms linking retinal vascular caliber with psychiatric diagnoses.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Article Pharmacology & Pharmacy

Addressing Metabolic Comorbidity in Individuals With Intellectual and Developmental Disability on Antipsychotics A Clinical Case Series

Nicolette Stogios, Margaret K. Hahn, Yona Lunsky, Pushpal Desarkar, Sri Mahavir Agarwal

Summary: This case series reports on the clinical use of metformin in patients with intellectual and developmental disabilities (IDDs) on antipsychotics. The study found that patients experienced a mean weight loss of 11.1 kg while on metformin treatment, with over 50% achieving clinically meaningful weight loss of >7%.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2023)

Article Endocrinology & Metabolism

Thermoneutral housing and preexisting obesity do not abolish the sexually dimorphic effects of olanzapine on weight gain in mice

Ian Seguin, Kyle D. Medak, Hesham Shamshoum, Margaret K. Hahn, David C. Wright

Summary: This study aimed to determine whether housing mice at thermoneutrality and under conditions of preexisting obesity would uncover a greater obesogenic effect of the antipsychotic olanzapine (OLZ). The study found that irrespective of obesity, OLZ treatment attenuated weight gain and increased energy expenditure in male mice. In females with preexisting obesity, OLZ increased food intake and potentiated weight gain. Uncovering the mechanisms conferring resistance to weight gain in males may provide clues for approaches to counter the metabolic side effects of antipsychotics clinically.

OBESITY (2023)

Editorial Material Neurosciences

Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities

Nicolette Stogios, Margaret K. K. Hahn, Yona Lunsky, Pushpal Desarkar, Sri Mahavir Agarwal

JOURNAL OF PSYCHIATRY & NEUROSCIENCE (2023)

Review Psychiatry

Pharmacological Interventions for the Prevention of Antipsychotic-Induced Weight Gain in People With Schizophrenia: A Cochrane Systematic Review and Meta-Analysis

Sri Mahavir Agarwal, Nicolette Stogios, Guy E. J. Faulkner, Margaret Hahn

Summary: Patients with schizophrenia suffer from obesity, cardiovascular disease, and reduced life expectancy. The weight gain and metabolic adverse effects caused by antipsychotic medications exacerbate and accelerate these problems. Therefore, it is essential to develop safe and effective strategies for managing these issues as early as possible.

SCHIZOPHRENIA BULLETIN (2023)

Review Psychiatry

Depression in caregivers of patients with schizophrenia: a scoping review

Femin Prasad, Margaret K. Hahn, Araba F. Chintoh, Gary Remington, George Foussias, Martin Rotenberg, Sri Mahavir Agarwal

Summary: Caregivers of people with schizophrenia often experience depression, but their mental health is often overlooked. This review aimed to consolidate recent literature on the prevalence of depression in these caregivers, factors associated with depression, and interventions that target depression. The findings suggest a high prevalence of depression in caregivers, with several factors influencing its occurrence, and promising interventions showing a significant reduction in depression levels.

SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY (2023)

Article Pharmacology & Pharmacy

Enhancing endogenous levels of GLP1 dampens acute olanzapine induced perturbations in lipid and glucose metabolism

Kyle D. Medak, Alyssa J. Weber, Hesham Shamshoum, Greg L. McKie, Margaret K. Hahn, David C. Wright

Summary: This study aimed to determine if increasing endogenous GLP1 is sufficient to protect against acute olanzapine-induced impairments in glucose and lipid homeostasis. The researchers found that pharmacological approaches to increase endogenous GLP1 can reduce lipid and glucose metabolism disturbances caused by olanzapine. These findings suggest that increasing endogenous GLP1 through pharmacological means may be a useful adjunct approach to mitigate olanzapine-induced perturbations in lipid and glucose metabolism.

FRONTIERS IN PHARMACOLOGY (2023)

Article Psychiatry

Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study

Jiwon Lee, Kenya Costa-Dookhan, Kristoffer Panganiban, Nicole MacKenzie, Quinn Casuccio Treen, Araba Chintoh, Gary Remington, Daniel J. J. Mueller, Sanjeev Sockalingam, Philip Gerretsen, Marcos Sanches, Alla Karnovsky, Kathleen A. Stringer, Vicki L. L. Ellingrod, Ivy F. F. Tso, Stephan F. F. Taylor, Sri Mahavir Agarwal, Margaret K. K. Hahn, Kristen M. M. Ward

Summary: Psychosis spectrum disorders (PSDs) and other severe mental illnesses like bipolar disorder are associated with intrinsic metabolic abnormalities. Antipsychotics (APs), the main treatment for PSDs, can lead to additional metabolic issues including weight gain. This study used metabolomic profiles to identify biomarkers and explore the mechanisms of PSDs and AP-induced weight gain. The findings suggest that specific fatty acids may serve as biomarkers for PSDs and early predictors of AP-induced weight gain. These findings have important clinical implications for identifying individuals at risk and developing targeted treatments.

FRONTIERS IN PSYCHIATRY (2023)

Article Pharmacology & Pharmacy

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series

Femin Prasad, Riddhita De, Vittal Korann, Araba F. Chintoh, Gary Remington, Bjorn H. Ebdrup, Dan Siskind, Filip Krag Knop, Tina Vilsboll, Anders Fink-Jensen, Margaret K. Hahn, Sri Mahavir Agarwal

Summary: Metformin is the recommended first-line treatment for antipsychotic-associated weight gain (AAWG), but not all patients benefit from it. GLP1-RA has shown potential in managing obesity, and semaglutide, a weekly injectable GLP-1RA, has superior efficacy. This study explored the efficacy of semaglutide in AAWG and found significant weight loss in patients who did not respond to metformin. Further randomized control trials are needed to validate these findings.

THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2023)

Review Endocrinology & Metabolism

Antipsychotic-Induced Alterations in Lipid Turnover

Sandra Pereira, Emily Au, Sri Mahavir Agarwal, David C. Wright, Margaret K. Hahn

Summary: Schizophrenia is a debilitating psychiatric disorder that is treated with antipsychotics. However, these medications have been found to increase the risk of metabolic and cardiovascular disorders, partly due to their effects on lipid metabolism. This review summarizes the current understanding of how antipsychotics modulate lipid turnover at different levels and highlights the need for further research on the intracellular mechanisms involved.

ENDOCRINOLOGY (2023)

Review Pharmacology & Pharmacy

Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review

Raghunath Singh, Nicolette Stogios, Emily Smith, Jiwon Lee, Kateryna Maksyutynsk, Emily Au, David C. Wright, Giada De Palma, Ariel Graff-Guerrero, Philip Gerretsen, Daniel J. Muller, Gary Remington, Margaret Hahn, Sri Mahavir Agarwal

Summary: This scoping review examines the role of gut microbiota (GMB) in the pathophysiology of schizophrenia (SCZ) and metabolic alterations associated with antipsychotics (APs). The findings suggest that changes in GMB composition are associated with SCZ pathogenesis and AP-induced metabolic perturbations. Additionally, prebiotic and probiotic formulations show potential therapeutic benefits in improving SCZ symptoms and attenuating AP-induced metabolic alterations.

THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2022)

Article Neurosciences

Identifying the Common Genetic Basis of Antidepressant Response

Oliver Pain, Karen Hodgson, Vassily Trubetskoy, Stephan Ripke, Victoria S. Marshe, Mark J. Adams, Enda M. Byrne, Adrian I. Campos, Tania Carrillo-Roa, Annamaria Cattaneo, Thomas D. Als, Daniel Souery, Mojca Z. Dernovsek, Chiara Fabbri, Caroline Hayward, Neven Henigsberg, Joanna Hauser, James L. Kennedy, Eric J. Lenze, Glyn Lewis, Daniel J. Mueller, Nicholas G. Martin, Benoit H. Mulsant, Ole Mors, Nader Perroud, David J. Porteous, Miguel E. Renteria, Charles F. Reynolds, Marcella Rietschel, Rudolf Uher, Eleanor M. Wigmore, Wolfgang Maier, Naomi R. Wray, Katherine J. Aitchison, Volker Arolt, Bernhard T. Baune, Joanna M. Biernacka, Guido Bondolfi, Katharina Domschke, Masaki Kato, Qingqin S. Li, Yu-Li Liu, Alessandro Serretti, Shih-Jen Tsai, Gustavo Turecki, Richard Weinshilboum, Andrew M. McIntosh, Cathryn M. Lewis

Summary: Antidepressant response is influenced by common genetic variation, has a genetic overlap with schizophrenia and educational attainment, and provides a useful resource for future research.

BIOLOGICAL PSYCHIATRY: GLOBAL OPEN SCIENCE (2022)

暂无数据